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Background: The recent introduction of pathology tissue-chromatin immunoprecipitation (PAT-ChIP), a technique
allowing chromatin immunoprecipitation from formalin-fixed and paraffin-embedded (FFPE) tissues, has expanded
the application potential of epigenetic studies in tissue samples. However, FFPE tissue section analysis is strongly
limited by tissue heterogeneity, which hinders linking the observed epigenetic events to the corresponding cellular
population. Thus, ideally, to take full advantage of PAT-ChIP approaches, procedures able to increase the purity and
homogeneity of cell populations from FFPE tissues are required.
Results: In this study, we tested the use of both core needle biopsies (CNBs) and laser microdissection (LMD),
evaluating the compatibility of these methods with the PAT-ChIP procedure. Modifications of the original protocols
were introduced in order to increase reproducibility and reduce experimental time. We first demonstrated that
chromatin can be prepared and effectively immunoprecipitated starting from 0.6-mm-diameter CNBs. Subsequently,
in order to assess the applicability of PAT-ChIP to LMD samples, we tested the effects of hematoxylin or eosin
staining on chromatin extraction and immunoprecipitation, as well as the reproducibility of our technique when
using particularly low quantities of starting material. Finally, we carried out the PAT-ChIP using chromatin extracted
from either normal tissue or neoplastic lesions, the latter obtained by LMD from FFPE lung sections derived from
mutant K-rasv12 transgenic mice or from human adeno- or squamous lung carcinoma samples. Well characterized
histone post-translational modifications (HPTMs), such as H3K4me3, H3K27me3, H3K27Ac, and H3K9me3, were
specifically immunoselected, as well as the CTCF transcription factor and RNA polymerase II (Pol II).
Conclusions: Epigenetic profiling can be performed on enriched cell populations obtained from FFPE tissue
sections. The improved PAT-ChIP protocol will be used for the discovery and/or validation of novel epigenetic
biomarkers in FFPE human samples.
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Table 1 Fluorimetric quantification of chromatin isolated
from CNBs and control FFPE sections
Sample Chromatin (μg)
FFPE sections (n.4) 4.82
CNBs (n.4) 3.50
CNBs (n.1) 1.97
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The importance of epigenetic alterations in cancer, as
well as in many other diseases, has been strongly estab-
lished over the last decade. However, the epigenome and
its regulation, and the mechanisms responsible for their
alteration in cancer cells remain largely unknown [1-3].
To date, the majority of studies have been conducted on
cultured cells; however, this approach suffers from sev-
eral limitations, the most important being the appear-
ance of molecular alterations due to the cells' adaptation
to culture conditions [4,5].
In the last 20 years, chromatin immunoprecipitation
(ChIP) has become a powerful experimental strategy to
study the epigenome [6-10]. Total DNA obtained by
ChIP is mainly analyzed at the level of single sequences
by quantitative PCR (qPCR; locus-specific studies), or
‘genome-wide’ by ChIP-Seq, in order to investigate the
distribution of the protein of interest over the entire
genome [11,12].
These studies are producing an enormous amount of
complex information that is strongly contributing to the
elucidation of the epigenetic alterations involved in tumor
development. Indeed, many authors believe that the time
when epigenetic biomarkers (prognostic or even predict-
ive) and/or specific epigenetic targets will start to be used
in clinical practice is not far away [13,14].
Formalin-fixed paraffin-embedded (FFPE) samples are
routinely used for processing and storage of pathology
specimens. We have recently described the methodology,
and the first application, of a new experimental proced-
ure named pathology tissue-chromatin immunoprecipi-
tation (PAT-ChIP), which shows that a ChIP assay can
be carried out using chromatin obtained from FFPE
samples [15,16]. However, a limitation of this applica-
tion, common to all applications in which FFPE slides
are used as starting material, is the heterogeneity of the
tissue of interest. For example, tumor samples are com-
monly characterized by the presence of a variable amount
of normal cells; this can prevent the correct identification
of the cellular population contributing to a specific
phenomenon. Different approaches can be employed
to solve this problem. For example, tissue core needle
biopsies (CNBs) directly obtained from paraffin blocks
represent a good technical option to increase the pur-
ity of a cellular population. This technique has been
widely exploited in the last years for applications like
tissue microarrays [17,18]. After determining the region
of interest, by histological staining or immunostaining of a
first tissue slide, CNBs of variable diameters can be
punched and recovered. The main limitation of this tech-
nique consists in the impossibility to know the precise
composition of an entire CNB, as this can vary when mov-
ing from the first slide towards the inside of the paraffin
block. A good alternative to this approach is representedby laser microdissection (LMD). This method exploits dir-
ect microscopic visualization to select, by laser cut, a
highly enriched cellular subpopulation from the FFPE
slides. Prior to excision, the slides are usually stained in
order to localize the region and cellular components of
interest. In addition, immunohistochemistry can be per-
formed in those cases where antibody usage does not
interfere with downstream applications [19,20]. In this
study, we evaluated the possibility to apply PAT-ChIP to
CNB and LMD samples.
Results
Application of PAT-ChIP to the study of core needle
biopsies
We first evaluated the application of PAT-ChIP to CNBs
obtained from FFPE samples (spleens) derived from a
murine model of acute promyelocytic leukemia (APL).
The spleen CNBs (0.6 mm in diameter) were fragmented
by sonication (15 pulses of 15 s at 85% of amplitude):
probably due to a lower specific surface than a FFPE
section of equal tissue volume, a CNB needs to be son-
icated by applying a higher total energy (i.e., longer
total time and higher amplitude) than that normally
used for a 10-μm-thick FFPE tissue section (three pulses
of 30 s at 40% of amplitude). Using these conditions, we
were able to isolate from CNBs an amount of chromatin
comparable with that usually obtained from FFPE sections
(Table 1).
The mean fragment size obtained using CNBs was ap-
proximately 300–400 bp, whereas using FFPE sections,
we obtained an average of about 500 bp: both fragments
sizes are considered acceptable for what is normally re-
quired for ChIP assays (Figure 1A). Chromatin obtained
from the CNBs was assayed by ChIP, taking advantage of
a widely studied anti-histone H3K4me3 antibody that we
had already tested for PAT-ChIP on the same FFPE
spleen sections [15]. The total amount of DNA was mea-
sured, and the target DNA was expressed as the ratio of
immunoprecipitated DNA relative to the input DNA,
obtaining similar values for CNBs or FFPE sections
(average values ranged between 1.2% and 1.4%); in con-
trast, no DNA was detected after ChIP assays in the ab-
sence of the antibody (mock) (Figure 1B).
The specificity of the immunoprecipitation assays was
further investigated by qPCR amplifying the promoter re-
gion of four genes already used and validated in previous
Figure 1 Evaluation of the applicability of PAT-ChIP to core needle biopsies (CNBs). Chromatin was extracted from one CNB or from a pool
of four CNBs (0.6-mm diameter, 1-mm thickness) and from a pool of four FFPE tissue slides (sections, 10-μm thick) deriving from the same FFPE
sample of mouse leukemic spleen. Chromatin was immunoprecipitated with an anti-H3K4me3 antibody, and the resulting purified DNA was
analyzed by qPCR for enrichment at specific loci. (A) Evaluation of chromatin fragmentation by electrophoretic separation on 1.3% agarose
gel electrophoresis (AGE) followed by ethidium bromide staining of purified input DNA. MKs, molecular weight markers. (B) Total amount of
DNA obtained by PAT-ChIP using an anti-H3K4me3 antibody, expressed as the ratio between bound and input DNA (percentage; mean values obtained
from experiment conducted in triplicate). Mock, no antibody; *, not detectable. (C) Amplification of transcriptionally active (Actb and Gapdh) and inactive
(Hapln1 and Col2a1) promoter regions by real-time qPCR (each sample amplified in triplicate). Enrichments of the promoter sequences associated with
the indicated genes for H3K4me3 (Mock, no antibody) are expressed as the bound/input ratio (percentage).
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(Actb) and glyceraldehyde-3-phosphate dehydrogenase
(Gapdh)) and two genes known to be silent in the mouse
spleen (hyaluronan and proteoglycan link protein 1
(Hapln1) and collagen, type II, alpha 1 (Col2a1)) enriched
or not enriched for H3K4me3 [15,16]. In all the IP sam-
ples, we found a specific and comparable enrichment of
the two housekeeping genes against the silent ones andthe absence of amplification in the control mock samples
(Figure 1C and Additional file 1).
Evaluation of chromatin preparation from very small
tissue samples
Very small tissue samples (such as those obtained by
LMD) can be a very critical source of chromatin. To
check the protocol for a quantitatively limited source of
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nical bias that might affect the procedure, we scale-
down the starting material (from FFPE slides) usually
used for chromatin extraction. We used the samples de-
rived from the murine transgenic K-rasv12 lung carcin-
oma model, which, due to tissue heterogeneity, are
better candidates for LMD approaches than APL sam-
ples [21]. Chromatin was extracted from murine lung tu-
mors (FFPE slides) starting from the equivalent of 4×,
2×, 1×, 0.5×, and 0.25× FFPE lung sections. Fluorimetri-
cal measurements of the isolated chromatin were per-
formed prior to (chromatin) and after decrosslinking
and DNA purification (DNA). As shown in Table 2, we
found strong reproducibility and linearity between the
quantity of starting FFPE tissues and the amount of
chromatin obtained (see also Figure 2A).
Chromatin fragmentation was also evaluated and,
again, the different samples produced a similar frag-
ment size distribution, with a mean around 500 bp
(with the exception of the sample corresponding to the
0.25× section which appears undetectable due to the
extremely low amount of material; Figure 2B).
Evaluation of the compatibility with histological staining
Tissue sections are stained with hematoxylin alone or
coupled with eosin prior to laser microdissection. In
order to establish if hematoxylin or eosin staining proce-
dures could affect chromatin isolation and ChIP results,
we performed parallel chromatin extractions and immu-
noprecipitations using four 10 μm FFPE sections, previ-
ously stained with hematoxylin or eosin (routine staining
procedures) or left unstained as controls. We first evalu-
ated the possible interference of the staining with the
chromatin extraction and found no significant changes
on the efficiency of chromatin isolation (Table 3 and
Figure 3A).
Subsequently, the chromatin was immunoprecipitated
with an anti-H3K4me3 antibody, obtaining comparable
results among all the samples in terms of DNA enrich-
ment and absence of signal in mock controls (Figure 3B).
The quality of the ChIP was also assessed by locus-
specific qPCR, which showed a highly specific enrich-
ment of H3K4me3 at expressed genes (Actb and Gapdh;
Figure 3C and Additional file 2).Table 2 Fluorimetric quantification of chromatin isolated
from different amounts of starting material
FFPE section number Isolated chromatin (μg) DNA (μg)
4 1.32 1.18
2 0.68 0.86
1 0.28 0.30
0.5 0.11 0.13
0.25 0.07 0.08Application of PAT-ChIP to the study of LMD samples
Finally, we assessed the applicability of PAT-ChIP to the
LMD samples. To this end, a pilot experiment was con-
ducted using 40 FFPE lung sections (6 μm each) derived
from a K-rasv12 transgenic mouse; LMD was used to iso-
late tumor cells and normal cells from the FFPE sections
(Figure 4A). Subsequently, immunoprecipitation assays,
with either an anti-H3K4me3 or an anti-H3K9me3 anti-
body, were performed using chromatin (150 ng/assay)
obtained from both normal and tumor LMD cells (as a
control, a whole, not microdissected, FFPE lung section
was used; Table 4). Importantly, all the chromatin sam-
ples, isolated from the different parts of the tissue sec-
tions, showed a homogeneous fragmentation, with a
mean fragment size of about 300–400 bp in both micro-
dissected samples (normal and tumor); a similar size was
also found in the control chromatin (Ctrl, Figure 4B).
Due to the lower amount of chromatin used in com-
parison to the standard condition of PAT-ChIP, we de-
cided to omit the final fluorimetrical quantitation in
order to put aside sufficient material for subsequent ana-
lyses. Analysis by qPCR showed a specific immunoselec-
tion in all samples, with high levels of H3K4me3 found
at the expressed genes (Actb and Gapdh), and H3K9me3
enrichment at a heterochromatic genomic region (major
satellite) (Figure 4C,D and Additional file 3, panels A
and B). In order to further verify the specificity of the
immunoprecipitation, we analyzed the distribution of
H3K4me3 in regions located upstream and downstream
the transcription start sites (TSSs) of the beta-actin and
Gapdh genes. In fact, as also reported in our previous
study [15], H3K4me3 is a histone post-translational
modification (HPTM) usually distributed in the proxim-
ity of TSSs (with the majority of peaks located in a win-
dow of ±2.5 Kb from the RefSeq annotated TSSs). As
expected, genomic regions upstream and downstream
the TSS of both beta-actin and Gapdh genes are less
enriched in H3K4me3 than the TSS-containing region
(Figure 4E).
Applicability of PAT-ChIP to LMD-FFPE samples was
then further evaluated testing a panel of chromatin-related
proteins (both additional HPTMs, such as H3K27me3 and
H3K27Ac, and non-histone proteins, such as the transcrip-
tional factor CTCF and RNA polymerase II), revealing spe-
cific immunoselection (Figure 4F,G and Additional file 4,
panels A and B). Chromatin was isolated as described
above from a further 120 FFPE lung sections (6 μm each).
After immunoselection, the transcriptionally active genes
were found to be enriched in H3K4me3, H3K27Ac,
and Pol II PAT-ChIPs, while the repressed genes were
found enriched, exclusively, in the H3K27me3 PAT-
ChIP (Figure 4F and Additional file 4, panel A). Moreover,
PAT-ChIP carried out using an anti-CTCF antibody
showed the specific immunoprecipitation of two known
Figure 2 Setting of chromatin extraction conditions for low-quantity of starting material. After pre-fragmentation of tissue from FFPE slides
taken from the lung of a 9-month-old K-rasv12 transgenic mouse, total tissue lysate was divided in parts equivalent to the material present in the
slide number reported in the figure (4, 2, 1, 0.5, or 0.25) and subjected to chromatin extraction. (A) Correlation between the number of FFPE slides
used as starting material and the amount of isolated chromatin before (left panel) and after (right panel) DNA purification. (B) Evaluation of
chromatin fragmentation by electrophoretic separation on 1.3% AGE followed by ethidium bromide staining of purified DNA. MKs, molecular
weight markers.
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tory regions (Figure 4G and Additional file 4, panel B).
Finally, in order to further investigate the applicability
of PAT-ChIP to LMD-FFPE samples, we performed both
H3K4me3 and H3K27me3 immunoprecipitations using
chromatin isolated from human lung tumor FFPE samples.Table 3 Fluorimetric estimation of the quantity of
chromatin isolated from stained or unstained samples
Sample Chromatin (μg)
Control (not stained) 1.02
Eosin 1.38
Hematoxylin 1.04Six FFPE sections (6 μm each) of either human lung
adenocarcinoma or human lung squamous carcinoma
samples (Figure 5A) were subjected to LMD to isolate
tumor cells and normal cells. Two hundred nanograms
of chromatin isolated from both either the normal or the
LMD tumor components was immunoprecipitated with
an anti-H3K4me3 or anti-H3K27me3 antibody (a non-
related antibody ChIP was performed as control only for
the lung adenocarcinoma, due to the very low amount of
chromatin isolated from the lung squamous carcinoma
FFPE sample; Table 5). Similar to the chromatin isolated
from the mouse model, the chromatin isolated from the
different components of the human tissue sections
showed a homogeneous fragmentation (Figure 5B). As
shown in Figure 5C (and Additional file 5), in both the
Figure 3 Evaluation of the applicability of PAT-ChIP to eosin- or hematoxylin-stained tissue slides. Chromatin was extracted from four
10-μm tissue slides stained either with eosin or hematoxylin, or not stained (Ctrl), prepared starting from the same FFPE lung sample taken
from a 9-month-old K-rasv12 transgenic mouse. Chromatin was then immunoprecipitated with the anti-H3K4me3 antibody and the resulting
purified DNA analyzed by qPCR for enrichment at specific loci. (A) Evaluation of chromatin fragmentation by electrophoretic separation on 1.3% AGE
and by ethidium bromide staining of purified input DNA. MKs, molecular weight markers. (B) Total amount of DNA obtained by PAT-ChIP by
using an anti-H3K4me3 antibody, expressed as the ratio between bound and input DNA (percentage; mean values obtained from experiment
conducted in triplicate). Mock, no antibody; *, not detectable. (C) Amplification of transcriptionally active (Actb and Gapdh) and inactive (Hapln1
and Col2a1) promoter regions by real-time qPCR (each sample amplified in triplicate). Enrichments of the promoter sequences associated with
the indicated genes for H3K4me3 (Mock, no antibody) are expressed as the bound/input ratio (percentage).
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cific immunoselection, characterized by high levels of
H3K4me3 associated with transcriptionally active genes
(vinculin (Vcl), glyceraldehyde-3-phosphate dehydrogen-
ase (Gapdh)), and H3K27me3 enrichment was observed at
regulatory regions of genes expected to be non-expressed
(hyaluronan and proteoglycan link protein 1 (Hapln1),
tumor necrosis factor receptor superfamily member 11b
(Tnfrsf11b)).Discussion
Due to the intrinsic heterogeneity of FFPE samples, po-
tential applications of PAT-ChIP could be hampered.
Therefore, we decided to investigate CNBs and LMD
samples as more homogeneous sources of chromatin.
As mentioned, the thickness of CNBs required us to
push the setting used for tissue fragmentation. However,
the physical stress induced by sonication at higher en-
ergy levels might alter the antigenicity of chromatin
Figure 4 (See legend on next page.)
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Figure 4 Application of PAT-ChIP to mouse LMD samples. Forty tissue slides were prepared from the lung of K-rasv12 transgenic mouse and
subjected to LMD to isolate both normal and tumor cells. Chromatin was immunoprecipitated with the reported antibodies and the DNA analyzed
by real-time qPCR for enrichment at specific loci (each sample amplified in triplicate). Enrichments of the amplified sequences are expressed as
the ratio between bound and input (percentage). (A) Representative hematoxylin and eosin staining of the lung of one mice in which the
expression of the oncogene was induced with 4-hydroxytamoxifen (4-OHT, right panel). (B) Evaluation of chromatin fragmentation by 1.3%
AGE and SYBR® Gold staining of DNA purified from unbound fractions after ChIP with the H3K4me3 antibody. (C) Amplification of transcriptionally
active (Actb and Gapdh) and inactive (Hapln1 and Col2a1) promoter regions after H3K4me3 immunselection. Mock, no antibody. (D) Amplification of
transcriptionally active (Actb and Gapdh) and inactive (Hapln1 and Col2a1) promoter regions, and major satellite, after H3K9me3 immunoselection Mock,
no antibody. (E) Amplification of regions located upstream and downstream from the transcription start site (TSS; at the indicated distance from TSS, see
also Table 6) of the beta-actin and Gapdh genes, after H3K4me3 immunoselection. (F) Amplification of transcriptionally active (Actb and Gapdh)
and inactive (Hapln1 and Col2a1) gene promoter regions, and major satellite sequence, after H3K4me3, H3K27me3, H3K27Ac, and Pol II
immunoselections. Mock, no antibody; n.r. Ab, non-related antibody. (G) Amplification of two CTCF binding sites (CTCF-BS of DNA-methyltransferase
3a (Dnmt3a) and DNA-methyltransferase 1 (Dnmt1) genes) and two CTCF unrelated genomic regions as controls (CTCF neg. sequences 1 and 2), after
CTCF immunoselection. Mock, no antibody; n.r. Ab, non-related antibody).
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and/or loss of the epitopes recognized by the antibody.
A sign of the increased level of physical stress to which
the chromatin was subjected in our experiments was
the higher level of fragmentation reached with respect
to control slides. Notably, the efficiency of chromatin
isolation seems to increase with smaller amounts of
CNB-derived samples, as demonstrated by comparing
the total amount of chromatin obtained from one and
four CNBs (Table 1).
Interestingly, although both samples originated from
the same paraffin block, the expressed genes showed an
apparent lower level of H3K4me3 enrichment when the
ChIP was performed using CNBs instead of tissue sec-
tions (Figure 1C). This lower enrichment could be the
result of structural changes in the chromatin—due to
the higher energy used for sonication (e.g., affecting the
integrity of the epitopes recognized by the antibody)—
which, however, do not prevent a clear discrimination
between expressed and silent genes.
The use of CNBs is not devoid of limitations. The
main limit consists in the impossibility of knowing, pre-
cisely, the cellular composition of the underlying tissue.
Thus, we also considered the use of LMD: unlike
CNBs, LMD allows the direct separation and collection
of different cell populations from the same tissue sec-
tion, thus reaching higher levels of purity. LMD is now a
well-established technique, and it is used in conjunction
with many different downstream applications (e.g., DNA
genotyping and loss of heterozygosity (LOH) analysis,
DNA methylation analysis, RNA transcript profiling,Table 4 Fluorimetric quantification of chromatin isolated
from normal and LMD tumor tissue fractions
Sample Chromatin (μg)
Normal tissue 3.56
LMD tumor 0.44cDNA library generation, proteomics discovery, and
signal-pathway profiling [19]).
As a preliminary step, we verified whether the proced-
ure could maintain its linearity in terms of total amount
of extracted chromatin, and, importantly, if it produces a
comparable chromatin fragmentation in function of the
progressive reduction of the tissue dimensions. The in-
vestigation of this aspect was, in our opinion, of funda-
mental importance, since chromatin isolation could have
been strongly affected by sonication performance and
micrococcal nuclease digestion efficiency (used at a fixed
enzyme concentration). Interestingly, we found that, at
least within the range of amounts of material tested,
chromatin extraction maintains an almost perfect linear-
ity in terms of quantities of isolated chromatin. Similarly,
chromatin fragmentation does not seem to be affected,
indicating that the same concentration of micrococcal
nuclease can be used irrespective of variations in the
quantities of starting material. This last observation is very
useful, since it will allow a better standardization of the
entire chromatin extraction procedure, especially import-
ant when the amount of starting tissue is not quantifiable.
We thus applied the PAT-ChIP procedure to LMD
lung tumor samples originating from the K-rasv12 trans-
genic mouse model using six different antibodies; not-
ably, the LMD procedure did not impair the analysis by
ChIP of the extracted chromatin, even when studying
very small amounts and after histological staining. We
also found that in addition to HPTMs, non-histone pro-
teins such as Pol II and the transcription factor CTCF
can be investigated in LMD samples. Most importantly,
we demonstrated that the procedure can be used to in-
vestigate HPTMs in human archival samples.
Currently, a limitation of our approach to study LMD
FFPE samples is that is limited to specific loci. In fact,
probably due to the more extensive crosslinking procedure
routinely applied to human FFPE tissues (normally fixed by
using 4% of formaldehyde for a variable incubation time
ranging between 16 and 48 hours), the isolation of
Figure 5 Application of PAT-ChIP to human LMD samples. Six tissue slides (6 μm thick) were prepared from both human FFPE lung
adenocarcinoma (AC) and FFPE lung squamous carcinoma (SC) tissues and subjected to LMD to isolate normal and tumor cells. Chromatin was
then immunoprecipitated with anti-H3K4me3 and anti-H3K27me3 antibodies, and the resulting purified DNA was analyzed by real-time qPCR for
enrichment at specific loci. (A) Representative H&E staining of the two human FFPE lung samples. (B) Evaluation of chromatin fragmentation by
electrophoretic separation on 1.3% agarose gel and SYBR® Gold staining of DNA purified only from H3K4me3 unbound fractions. (C) Amplification
of transcriptionally active (Vcl and Gapdh) and inactive (Hapln1 and Col2a1) promoter regions by real-time qPCR (each sample amplified in
triplicate). Enrichments of the promoter sequences associated with the indicated genes for H3K4me3 (n.r. Ab, non-related antibody) are
expressed as the ratio between bound and input (percentage).
Table 5 Quantification of chromatin isolated from normal
or LMD tumor components of human lung tumor
samples
Sample Chromatin (μg)
Lung adenocarcinoma
Normal 0.87
LMD tumor 0.69
Lung squamous carcinoma
Normal 0.43
LMD tumor 0.51
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an increased number of sonication steps. Thus, epigenomic
profiling by ChIP-Seq will require further optimization of
the protocol. From a translational point of view, however,
the access to small quantities of patient samples for chro-
matin studies will allow to validate candidate loci found
through other approaches (epigenomic profiling of cell
lines/fresh samples, PAT-ChIP from FFPE samples, etc.).
Conclusions
The data reported in the present work demonstrate that
different cell populations from heterogeneous FFPE tissue
slides when isolated by CNBs or LMD can be investigated
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adds new experimental potential to the PAT-ChIP tech-
nique and provides further tools to elucidate the role of
epigenetic alterations in malignant transformation and
tumor development. We believe that the diffusion of this
technique will also contribute to the identification of new
biomarkers and novel therapeutic strategies against cancer
and other diseases.
Methods
Preparation of FFPE tissues from APL and lung cancer
mouse models and human tumor samples
Leukemic blasts were isolated from APL transgenic mice
and i.v. injected (1 × 106 cells) in syngeneic recipient mice
to induce secondary leukemias [22]. When a massive
splenomegaly was established (usually, ≥9 days after injec-
tion), the mice were sacrificed: the spleens were collected,
rapidly washed in PBS, and incubated 16 h at room
temperature in 4% formaldehyde (FA) solution.
Induction of the K-rasv12 oncogene, in K-ras(+/LSLG12Vgeo);
RERTn(ert/ert) expressing mice, was achieved by intra-
peritoneal administration of 4-OHT (0.5 mg/injection, three
times/week for 2 weeks). Lesions with a progressively more
malignant phenotype (hyperplasia, adenomas, and adenocar-
cinomas) can be evidenced in the lungs from 4-OHT-
treated mice 9 months following administration [21].
FA-fixed samples were then routinely dehydrated in
a graded ethanol series (70%, 80%, 90%, and 100% -
absolute ethanol) and included in paraffin through an
automated tissue processor (Leica ASP300, Buffalo
Grove, IL, USA) [15]. CNBs with a diameter of 0.6 mm
and a width/thickness of 1 mm were produced from
mouse spleens, corresponding to a volume of tissue of
about 0.28 mm3 (which is approximately the same volume
of tissue present in a spleen section with 5 mm× 5 mm×
10 μm size, used as control).
Primary human lung tumors and normal tissues were
obtained from two patients who underwent surgery for
therapeutic purposes at the Fondazione IRCCS Ca'
Granda Ospedale Maggiore Policlinico (Milan, Italy).
The patients provided informed consent, approved by
the IRB of the Fondazione IRCCS Ca' Granda, and did
not receive neoadjuvant chemotherapy and/or radiother-
apy. The samples were fixed in formalin for no more
than 24 h, dehydrated by increasing concentrations of
ethanol (95% and 100%), and subsequently included in
paraffin for the diagnostic procedures. The two cases
were diagnosed as lung adenocarcinoma (AC) and squa-
mous cell carcinoma (SC), respectively. The samples
were used for LMD experiments as described below.
Experiments involving animals were performed in accord-
ance with the Italian Laws (D.L.vo 116/92 and following
addition), enforcing the EU 86/609 Directive (Council
Directive 86/609/EEC of 24 November 1986 on theapproximation of laws, regulations, and administrative
provisions of the Member States regarding the protec-
tion of animals used for experimental and other scien-
tific purposes). The mice were housed accordingly to
the guidelines set out in Commission Recommenda-
tion 2007/526/EC - June 18, 2007 on guidelines for the
accommodation and care of animals used for experimen-
tal and other scientific purposes. The project was notified
to the Italian Ministry of Health (Project number: 21/10).
Laser microdissection
The FFPE tissues were morphologically examined by
hematoxylin/eosin (H&E) staining, and the neoplastic le-
sions were identified before LMD. For LMD, the FFPE
samples were cut into 6-μm sections, which were imme-
diately placed on specific LMD UV-treated glass slides
with PEN membranes (Leica Microsystems) and deparaf-
finized by incubation in xylene (Carlo Erba, Milan, Italy)
for 1 min. Tissue sections were subsequently rehydrated
in decreasing concentrations of ethanol (100%, 95%, and
75%) and rinsed in deionized water for 30 s. The slides
were stained with hematoxylin for 1 min, washed in de-
ionized water, and dehydrated by incubation in 75%
ethanol for 30 s. Each step was performed at room
temperature. Neoplastic lesions were isolated and sepa-
rated from the normal lung tissue using the LMD 6000
system (Leica Microsystems), as previously described
[23]. Microdissected samples were collected into the cap
of 0.2-ml microcentrifuge tubes and stored at 4°C.
Chromatin extraction from FFPE tissues
Chromatin extraction was performed following the ori-
ginal PAT-ChIP protocol [15,16] with minor modifica-
tions. The FFPE tissues were first deparaffinized by
sequential incubations (five times) for 10 min in 1 ml of
histolemon solution (Carlo Erba) at room temperature.
The samples were rehydrated by decreasing concentra-
tions of ethanol starting from 100% through to 95%,
70%, 50%, 20%, and water (10 min at room temperature
for each step). The rehydrated samples were resus-
pended in 0.5 ml of lysis buffer (1× Tris-buffered saline
(TBS), 0.5% Tween 20, 0.1 mM phenylmethylsulfonyl
fluoride (PMSF), and 10 μg/mL RNase A) and incubated
for 30 min at room temperature with rotation. After
centrifugation at 17,860 × g for 3 min at 4°C, the samples
were resuspended in 0.3 ml of digestion buffer (50 mM
Tris-HCl (pH 7.4), 0.32 M sucrose, 4 mM MgCl2, 1 mM
CaCl2, 0.1 mM PMSF) and fragmented by sonication
(3 cycles of 30 s on and 60 s off ) at 40% amplitude in
a −20°C thermoblock, using an EpiShear sonicator
(Active Motif, Carlsbad, CA, USA). Chromatin digestion
was carried out by adding 2.5 U/ml of micrococcal nucle-
ase (N.70196Y; USB) and incubating for 1 min at 37°C.
After centrifugation at 17,860 × g for 3 min at 4°C, the
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fer (1× TBS, 0.1% sodium dodecyl sulfate (SDS)), sonicated
18 times for 5 s (10 s off) in −20°C thermoblock with an
amplitude of 85% to extract chromatin, and cleared by cen-
trifugation. The supernatant containing chromatin was col-
lected, and the chromatin was fluorimetrically quantified
by Qubit (Invitrogen, Carlsbad, CA, USA).
Chromatin was also extracted from tissue CNBs,
following the same procedure, with the exception of
the pre-fragmentation step, which was carried out by
sonicating the samples 15 times for 15 s at 85% amp-
litude. The preparation of both eosin- or hematoxylin-
stained lung samples and LMD samples was conducted
starting directly from the rehydration (75% ethanol)
instead of deparaffination step. In addition, tissue pre-
fragmentation was performed by sonicating the sam-
ples 12 times for 30 s at 40% amplitude. All the other
steps of the experiment were carried out following the
same procedure described above, with the exception of
the final sonication step that was performed by sonicating
the samples 24 times for 5 s (10 s off for murine lung sam-
ples) or 48 times for 5 s (10 seconds off for human lung
samples) in −20°C thermoblock with 85% amplitude.
The evaluation of the efficiency of chromatin extrac-
tion from small quantities of the starting material was
conducted using the same pool of pre-fragmented tissue
slides. The sonicated samples were divided, prior to nu-
clease digestion, into different parts (in order to obtain
the amount of material of 4, 2, 1, 0.5, or 0.25 tissue
slides). Nuclease digestions were performed in parallel
with the same amount of micrococcal nuclease enzyme
(2.5 U). The rest of the experiment was conducted fol-
lowing the procedure described above.
Chromatin immunoprecipitation and DNA isolation
Chromatin was immunoselected in incubation buffer
(20 mM Tris-HCl (pH 7.4), 50 mM NaCl, 5 mM Na2EDTA,
and 0.1 mM PMSF) using 150–300 ng of chromatin for
each assay (dependent on either the amount of chromatin
extracted from FFPE samples in each experiment or theTable 6 List and sequences of primers employed for qPCR ass
Organism Gene Forward primer sequence
Mouse Actb 5′-TTCCAGGCCCTCCCTCAT-3′
Mouse Actb 5′-GACCTCTATGCCAACACAGTGC-3′
Mouse Gapdh 5′-CAGATCAGCTGCCTGTGTGG-3′
Mouse Gapdh 5′-TCTTTCCCTTAAACAGGCCCA-3′
Human Vcl 5′-ATGCCAGTGTTTCATACGCG-3′
Human Gapdh 5′-TTCGCTCTCTGCTCCTCCTG-3′
Human Hapln1 5′-TCGGATGCTCTCAAGTTCTGC-3′
Human Tnsrsf11b 5′-GTGAAGGGAACAGTGCTCCG-3′number of ChIP assays to perform) and incubated for 16 h
at 4°C on a rotating platform with anti-H3K4me3 (39159,
Lot. 01609004; Active Motif), anti-H3K9me3 (39161, Lot.
13509002; Active Motif ), anti-H3K27me3 (07–449,
Lot. DAM1514011; Millipore, Billerica, MA, USA), anti-
H3K27Ac (ab4729, Lot. GR55451-1; Abcam, Cambridge,
MA, USA), anti-polymerase II (ab5130-50, Lot. 948723,
Abcam), anti-CTCF (07–729, lot. DAM1772428; Millipore),
and normal rabbit IgG (Sc-2027, Lot. l2310; Santa Cruz,
Dallas, TX, USA) antibody. Forty microliters of 50% v/v
slurry rec-Protein G-Sepharose 4B Conjugate (pre-incubated
for 16 h at 4°C with 1 mg/mL of BSA in incubation buffer;
Invitrogen) was added to each ChIP assay and incubated for
3 h at 4°C. After centrifugation, the pellets were
washed sequentially with 10 mL of washing buffer A
(20 mM Tris-HCl (pH 7.4), 1% TritonX-100, 50 mM
NaCl, 5 mM Na2EDTA, and 0.1 mM PMSF), 10 mL of
washing buffer B (50 mM Tris-HCl (pH 7.4), 1% TritonX-
100, 100 mM NaCl, 10 mM Na2EDTA, and 0.1 mM
PMSF), and 10 mL of washing buffer C (50 mM Tris-HCl
(pH 7.4), 1% TritonX-100, 150 mM NaCl, 10 mM
Na2EDTA, and 0.1 mM PMSF). Elution was carried
out by adding 220 μL of elution buffer (1× Tris-EDTA
(TE)/1% SDS) and incubating for 30 min at room
temperature on a rotating platform. After centrifuga-
tion, the supernatant was recovered, and the elution
was repeated with 130 μL of elution buffer to obtain a
final volume of 350 μL (bound fraction).
The bound fractions and previously saved inputs (5%)
were decrosslinked through overnight incubation at
65°C in elution buffer/0.2 M NaCl, followed by diges-
tion with 0.1 mg/mL proteinase K (3 h at 45°C). DNA
purification was carried out using the PCR purification
kit (Qiagen, Venlo, The Netherlands) following manufac-
turer's instructions, and the DNA was fluorimetrically
quantified by Qubit (Invitrogen).
DNA analysis
Chromatin fragmentation was checked by electrophor-
etic separation of DNA (decrosslinked and purified fromay
Reverse primer sequence bp from TSS
Start End
5′-GAACTTCCTGTCACAGTAGCAGGA-3′ −2,991 −2,891
5′-ATGGTGCTAGGAGCCAGAGC-3′ +2,548 +2,648
5′-GAAAGTCAGCCGAGCTGCATA-3′ −2,986 −2,886
5′-CGTGGTTCACACCCATCACA-3′ +2,528 +2,628
5′-CGCCCTCCTCGTGCATTAT-3′ +94 +184
5′-CCTAGCCTCCCGGGTTTCTC-3′ +95 +185
5′-TCGCCCAGAGACAAACTTAAGG-3′ +177 +267
5′-GCCCGTGCTATTCTGCATTC-3′ −540 −420
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scribed above) on a 1.3% agarose gel. The DNA was
stained alternatively with ethidium bromide or SYBR®
Gold stain (Invitrogen) as a function of the quantity of
DNA loaded (from 50 to 500 ng).
Purified DNA was analyzed by qPCR using the Fast
Start SYBR Green Master Mix (Roche, Basel, Switzerland)
and the Rotor-Gene 6000 robocycler (Corbett Life
Science, Sydney, Australia). Amplifications were car-
ried out using conditions and primer pairs described
in [15,24] or reported in Table 6. The data are re-
ported as the percentage of enrichment with respect
to the input.
Additional files
Additional file 1: Evaluation of the applicability of PAT-ChIP to core
needle biopsies (CNBs). Amplification of transcriptionally active (Actb
and Gapdh) and inactive (Hapln1 and Col2a1) promoter regions by
real-time qPCR (each sample amplified in triplicate). Enrichments of
the promoter sequences associated with the indicated genes for
H3K4me3 are expressed as fold occupancy relative to a non-enriched
region (Col2a; squared).
Additional file 2: Evaluation of applicability of PAT-ChIP to eosin- or
hematoxylin-stained tissue slides. Amplification of transcriptionally
active (Actb, Gapdh) and inactive (Hapln1 and Col2a1) promoter
regions by real-time qPCR (each sample amplified in triplicate). Enrichments
of the promoter sequences associated with the indicated genes for
H3K4me3 are expressed as fold occupancy relative to a non-enriched
region (Col2a; squared).
Additional file 3: Application of PAT-ChIP to mouse LMD samples.
(A) Amplification of transcriptionally active (Actb and Gapdh) and inactive
(Hapln1 and Col2a1) promoter regions by real-time qPCR. Enrichments of
the promoter sequences associated with the indicated genes for H3K4me3
are expressed as fold occupancy relative to a non-enriched region (Col2a;
squared). (B) Amplification of transcriptionally active (Actb and Gapdh) and
inactive (Hapln1 and Col2a1) promoter regions—in addition to the
heterochromatic major satellite sequence amplification—by real-time
qPCR (each sample amplified in triplicate). Enrichments of the amplified
sequences for H3K9me3 are expressed as fold occupancy relative to a
non-enriched region (Actb; squared).
Additional file 4: Application of PAT-ChIP to mouse LMD samples.
(A) Amplification of transcriptionally active (Actb and Gapdh) and
inactive (Hapln1 and Col2a1) promoter regions—in addition with the
heterochromatic major satellite sequence amplification—by real-time
qPCR. Enrichments of the amplified sequences for H3K4me3, H3K27me3,
H3K27Ac, and Pol II are expressed as fold occupancy relative to a
non-enriched region (Col2a or Actb, squared). (B) Amplification of
two CTCF binding sites (CTCF-BS of Dnmt3a and Dnmt1 genes) and
two CTCF unrelated genomic regions as controls (CTCF neg. sequences 1
and 2) by real-time qPCR (each sample amplified in triplicate). Enrichments
of the amplified sequences for CTCF binding are expressed as fold
occupancy relative to a non-enriched region (CTCF negative sequence 2;
squared).
Additional file 5: Application of PAT-ChIP to human LMD samples.
Amplification of transcriptionally active (Vcl and Gapdh) and inactive
(Hapln1 and Col2a1) promoter regions by real-time qPCR (each sample
amplified in triplicate). Enrichments of the promoter sequences associated
with the indicated genes for H3K4me3 are expressed as fold occupancy
relative to a non-enriched region (Col2a or Actb, squared).
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